CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

January 13, 2026 · PDUFA decision

TVTX PDUFA decision: a negative outcome, -14.6%

On January 13, 2026, Sparsentan — Travere Therapeutics, Inc. (Focal Segmental Glomerulosclerosis) reached its PDUFA decision. The result was a negative outcome, and the stock moved -14.6% in the window around the event.

The move

$34.10
1d before
$29.11
Event day
$28.93
1d after
$27.87
5d after

Pre-catalyst setup

-0.7%
30-day run-up
7235%
30-day volatility
2.0×
volume spike